Results 41 to 50 of about 6,879 (203)

The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. [PDF]

open access: yesPLoS ONE, 2013
Over the years, the knowledge regarding the relevance of the cannabinoid system to the regulation of metabolism has grown steadily. A central interaction between the cannabinoid system and ghrelin has been suggested to regulate food intake.
Lucia L Senin   +15 more
doaj   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats

open access: yes, 2010
The cannabinoid receptor 1 antagonist, rimonabant, reduces food intake and body weight, but contradictory findings have been reported as to whether the weight-reducing effect is fully accounted for by the reduced food intake or if rimonabant also ...
Malmlöf, Kjell,   +1 more
core   +2 more sources

The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease [PDF]

open access: yesMedicinski Podmladak, 2019
Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is hepatic manifestation of metabolic syndrome. It represents a spectrum of diseases ranging from steatosis, non-alcoholic steatohepatitis (NASH), that may progress to fibrosis, cirrhosis and ...
Brkić Dušan, Jorgačević Bojan
doaj  

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

open access: yesObesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed   +19 more
wiley   +1 more source

Rimonabant ยาใหม่เพอื่ ลดความเสี่ยงในระบบหัวใจและเมแทบอลิก [PDF]

open access: yes, 2008
การศึกษายาใหม่เพื่อป้องกันและรักษาโรคทางหัวใจและเมแทบอลิก (cardiometabolic diseases) ให้มีประสิทธิภาพดียิ่งขึ้นดำเนินต่อไป เพื่อลดปัจจัยเสี่ยงที่จะนำไปสู่การเกิด cardiometabolic diseases ยา rimonabant จัดเป็นยาตัวแรกในกลุ่ม cannabinoid1antagonist (CB1 ...
พันธุเวทย์, วิมล
core  

Acute rimonabant treatment promotes protein synthesis in C2C12 myotubes through a CB1‐independent mechanism

open access: yes, 2020
International audienceSarcopenia is an age-related loss of muscle mass associated with changes in skeletal muscle protein homeostasis due to lipid accumulation and anabolic resistance; changes that are also commonly described in obesity.
Kristell Combe   +9 more
core   +1 more source

Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory

open access: yesFrontiers in Pharmacology
Drug-associated pathological memory remains a critical factor contributing to the persistence of substance use disorder. Pharmacological amnestic manipulation to interfere with drug memory reconsolidation has shown promise for the prevention of relapse ...
Jiang Lin   +11 more
doaj   +1 more source

A novel chemical inhibitor suppresses breast cancer cell growth and metastasis through inhibiting HPIP oncoprotein

open access: yesCell Death Discovery, 2021
Increasing evidence suggests the pivotal role of hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) in cancer development and progression, indicating that HPIP inhibition may be a promising target for cancer ...
Pengyun Li   +12 more
doaj   +1 more source

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

open access: yesPharmaceuticals, 2010
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by ...
Fernando Cordido, Mª Luisa Isidro
doaj   +1 more source

Home - About - Disclaimer - Privacy